Business Recorder | Bayer's Investigational Riociguat Meets Primary Endpoint in Phase III Study of ... Sacramento Bee [1] The results were presented as a late-breaking abstract in an oral abstract session at CHEST 2012, the annual meeting of the American College of Chest Physicians (ACCP) in Atlanta, Georgia (Abstract No. 1462924). Chronic thromboembolic pulmon ary ... Bayer's Investigational Riociguat Meets Primary Endpoint in Phase III Study in ... Drug Helps in Two Types of Pulmonary Hypertension Bayer announces positive data from riociguat phase III study in patients with ... |
Wednesday, October 24, 2012
Bayer's Investigational Riociguat Meets Primary Endpoint in Phase III Study of ... - Sacramento Bee
cahijisebi.wordpress.com
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment